“This is a routine action that occurs when a potentially unexplained disease occurs in any test, while it is examined, ensuring that we maintain the integrity of the tests. In larger trials, illnesses occur by chance , But should be reviewed independently. To watch it carefully, “the company said in a statement to CNBC.
It said it was trying to speed up the review “to minimize any potential impact on test time”.
“We are committed to the safety of our participants and the highest standards of conduct in our tests,” the company said.
According to STAT News, following a suspected serious adverse reaction in a participant in the United Kingdom, a person familiar with the development said researchers reported that the grip was put on the test for “an abundance of caution”.
It is unclear how long the hold on the test will last. AstraZeneca began its testing at the end of last month and is one of three companies currently undergoing late testing for a potential vaccine. The other two are Pfizer and Moderna, which both began their tests in late July.
The US government announced on May 21 that it would pay up to $ 1.2 billion to AstraZeneca for its experimental vaccine developed with researchers at the University of Oxford. The US will receive at least 300 million doses of the vaccine as part of its investment.
AstraZeneca’s vaccine, called AZD 1222, uses genetic material from modified coronoviruses. It uses the techniques used to make the experimental Ebola vaccine, which was provided to the people in the Democratic Republic of Congo in late 2019.
In July, the company published data showing that its vaccine produced a promising immune response in an early-stage trial.
According to the researchers the vaccine was well tolerated and there were no serious adverse events. He said that fatigue and headaches were the most reported. Other common side effects include pain at the injection site, muscle pain, chills, and fever.
The development comes as polls suggest that Americans are already concerned about the safety of potential coronavirus vaccines.
According to a recent USA Today / Suffolk poll, two-thirds of voters say they will not receive a coronavirus vaccine as soon as it is available.
-CNBC’s Meg Tirrell contributed to this report.